On Friday, Shares of Bristol-Myers Squibb Co (NYSE:BMY), gained 1.37% to $64.49. 5.92 million shares of the company were exchanged.
Bristol-Myers Squibb (BMY) declared that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in England and Wales for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. Specifically, NICE recommended Daklinza, an oral, once-daily medication used in combination with other agents, to treat certain patients with HCV genotypes 1, 3 and 4.About 214,000 people in the UK are thought to have chronic HCV, and roughly 100,000 of those patients are estimated to have genotype 3, a difficult-to-treat and often aggressive form of chronic HCV.
HCV genotype 3 is associated with accelerated progression of fibrosis contrast to other genotypes,which can make treatment time critical. Recent research has also shown that the risk of cirrhosis for patients infected with HCV genotype 3 is 31% greater than for those with HCV genotype 1.
In the EU, Daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults. In genotype 3 HCV, Daklinza is presently approved in combination with sofosbuvir for 12 weeks in patients without cirrhosis and for 24 weeks in patients with cirrhosis with the optional use of ribavirin based on clinical assessment of the patient. Until recently, treatment options for genotype 3 patients in England were limited, and comprised of interferon. Daklinza plus sofosbuvir, with or without ribavirin, is presently one of only two all-oral treatment regimens recommended by the European Association for the Study of the Liver’s (EASL) treatment guidelines for patients with HCV genotype 3.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Shares of Mondelez International Inc (NASDAQ:MDLZ), inclined 1.93% to $45.85, during its last trading session.
Mondelēz International, declared the expansion of its Cocoa Life program in Côte d’Ivoire. In line with its commitment to empower 200,000 farmers and invest $400 million in Côte d’Ivoire and five other cocoa origins by 2022, Mondelēz International will partner with Barry Callebaut, the world’s leading manufacturer of chocolate and cocoa products, and Solidaridad, international development NGO, to scale up the implementing capacity of its holistic Cocoa Life program.
“This new partnership will allow us to quickly double the number of farmers we reach in Côte d’Ivoire in just two years from 2014,” said Cathy Pieters, Director of Cocoa Life at Mondelēz International. “Their complementary expertise will support our objectives of creating thriving cocoa communities while ensuring sustainable cocoa production.”
Barry Callebaut and Solidaridad will work hand in hand on the ground. Barry Callebaut will provide farmers with agricultural training and access to inputs to improve cocoa productivity and incomes, while Solidaridad will work together with the cocoa communities to design tailored community action plans and implement actions to strengthen livelihoods, empower women and promote children’s rights.
Mondelez International, Inc., through its subsidiaries, manufactures and markets snack food and beverage products worldwide. The company offers biscuits, including cookies, crackers, and salted snacks; chocolates, and gums and candies; powdered beverages and coffee; and cheese and grocery products.
At the end of Friday’s trade, Shares of Atmel Corporation (NASDAQ: ATML), declined -0.57% to $8.68.
It traded in a range of $8.68 and $8.79, exchanging hands with 6.09 million shares.
The stock is up 4.24% in this year through last close. In the trailing twelve months, net profit margin of the company was 2.50% while gross profit margin was 45.10%.
Atmel® Corporation (ATML), will release third quarter 2015 financial results on Wednesday, October 28, 2015 after the market close.
Atmel will not hold an earnings conference call due to its pending acquisition by Dialog Semiconductor.
Atmel Corporation designs, develops, manufactures, and sells semiconductor integrated circuit products primarily in the United States, Asia, Europe, South Africa, and Central and South America.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
